Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024GlobeNewsWire • 07/23/24
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation PlanGlobeNewsWire • 07/09/24
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsGlobeNewsWire • 07/02/24
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure ProductsGlobeNewsWire • 07/02/24
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 MillionGlobeNewsWire • 06/20/24
Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness DayGlobeNewsWire • 06/06/24
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024GlobeNewsWire • 05/10/24
Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job CutsInvestorPlace • 05/02/24
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial PositionGlobeNewsWire • 05/01/24
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to NaloxoneGlobeNewsWire • 05/01/24
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024GlobeNewsWire • 04/22/24
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid CrisisGlobeNewsWire • 03/28/24
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing FacilityGlobeNewsWire • 03/25/24